Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

Clinical lung cancer - 1 Jan 2018

Melosky Barbara, Popat Sanjay, Gandara David R

Abstract excerpt

The optimal treatment sequence for patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive (EGFR-M+) non-small-cell lung cancer (NSCLC) continues to evolve, related largely to an increasing number of breakthroughs and studies in the field. The efficacy of tyrosine kinase inhibitors in the treatment of these patients is well established; however, the treatment decision-making process is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Carcinogenesis
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Patient Selection

Share to Precision Medicine

Share to Quality of Life

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 28668205
DOI: 10.1016/j.cllc.2017.05.019

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.PMID 28668205Read ↗

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read ↗

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.Semantic proximity Read ↗

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Semantic proximity Read ↗

Treatment sequences in EGFR mutant advanced NSCLC.Semantic proximity Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

Treatment choice in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

EGFR-mutated NSCLC: A roadmap to treatment sequences.Semantic proximity Read ↗

Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC.Semantic proximity Read ↗

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy.Semantic proximity Read ↗

Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.